# Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

> **NCT06965309** · NA · TERMINATED · sponsor: **Shenzhen MagicRNA Biotechnology Co., Ltd** · enrollment: 9 (actual)

## Conditions studied

- Refractory Myasthenia Gravis

## Interventions

- **DRUG:** HN2301 injection

## Key facts

- **NCT ID:** NCT06965309
- **Lead sponsor:** Shenzhen MagicRNA Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2026-01-19
- **Primary completion:** 2026-02-11
- **Final completion:** 2026-02-11
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Change of registrant
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06965309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06965309, "Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06965309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*